VistaGen
Therapeutics is a San Francisco-based biotechnology company that focuses on
human stem cell technology for the purposes of drug rescue, predictive
toxicology, and drug metabolism screening. The company was founded in 1998 and
has spent the last 16 years establishing its reputation as an expert in human
pluripotent stem cell (hPSC) technology.
VistaGen
Therapeutics’ drug rescue efforts involve combining its hPSC technology with
the most up-to-date medicinal chemistry to generate new chemical variants of
drug candidates that were abandoned by biotechnology or pharmaceutical
companies before the market approval stage.
The drug candidates
in which VistaGen is interested include those that were abandoned because of
concerns about their effect on the heart and liver. VistaGen believes it can
work with these discontinued drug candidates to cost effectively generate new,
proprietary variants with reduced toxicity. The company’s end goal is to
generate a pipeline of Drug Rescue Variants™ and sell them to biotechnology and
pharmaceutical companies so that they can be further developed, approved, and
sold commercially.
VistaGen
Therapeutics is accomplishing its goals through the use of its hPSC technology
platform, called Human Clinical Trials in a Test Tube™. The technology allows
VistaGen to assess the Drug Rescue Variants’ heart and liver safety profiles.
Though there are
other technologies like this on the market, Human Clinical Trials in a Test
Tube™ is unique because it allows VistaGen to perform this task with greater
speed and precision than conventional testing technology. Often times,
companies spend decades and millions of dollars in drug candidates that only
result in failure. VistaGen’s model is designed to leverage third-party
investments, speed up the testing process, and recycle candidates that may have
only been a few steps shy of being successful.
VistaGen’s research
initiatives extend beyond its laboratories. In April 2014, the company
announced that it became a member of the Cardiac Safety Research Consortium, an
organization that supports research into the evaluation of cardiac safety of
medical products. VistaGen is committed to staying at the cutting edge of
cardiac safety, given that it is the lynchpin for the success of its proprietary
drug candidates.
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.
Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The Quality Stocks Daily Blog http://blog.qualitystocks.net
The Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment